{"name":"uniQure N.V.","slug":"uniqure","ticker":"QURE","exchange":"NASDAQ","domain":"uniqure.com","description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement wit","hq":"Amsterdam, Netherlands","founded":0,"employees":"221","ceo":"Matt Kapusta","sector":"Biotech","stockPrice":27.07,"stockChange":-2.1,"stockChangePercent":-7.2,"marketCap":"$1.7B","metrics":{"revenue":18093000,"revenueGrowth":127.3,"grossMargin":0,"rdSpend":140673000,"netIncome":-198971000,"cash":80240000,"dividendYield":0,"peRatio":-9.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"uniQure Announces FDA Approval of Etranacogene Dezaparvove for Hemophilia A","summary":"The FDA approved etranacogene dezaparvove for the treatment of hemophilia A in adults with a partial gene deletion of factor VIII.","drugName":"etranacogene dezaparvove","sentiment":"positive"},{"date":"2022-11-07","type":"earnings","headline":"uniQure Reports Third Quarter 2022 Financial Results","summary":"uniQure reported revenue of $13.4 million and a net loss of $44.6 million for the third quarter of 2022.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNa21ZQk5EXzVvSi1qdTIzTUZrWEttMFNpSXdsME1CLVhLTndPa3JNUDVjUXk5MlctRDZXYXFPcHVVNmNuQW1nbGx1Yk9oT3FxNjVGLVV6SHJ6NnMxdWdKX2xtX3FjWHZOUThwZHREUkxQeVRwdXBJa1ZFQnZtdU9oTWpFMkh6TUFObEdoWFFLYWNVbEptemFqeW5WRWhqMEdJNjJZZzRtMlJGWG12OGlqUnFLbGl2aXRBSUFQa254N042eXRWRmpwVW03akdtWFVPT0pwdFlpc2ZSaExrS3d6b3VqWjZiMjI1bXU2MTNSSjFPc2tfaTBYLTZQQWZqZnNXX1I2TXJYdmJjQl9W?oc=5","date":"2026-03-26","type":"pipeline","source":"GlobeNewswire","summary":"UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire","headline":"UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPZU4zRzQwRk1wZEhkcGpBR3dNakZHQjBtd0E2R01Ya0Y5WUZDT0FWVFppSkR2UkZ5aGFDZ2lBby1RYmZaQXdUX3d0Njl6UTRGX2NadTJUanFTQ3pFQmI3X0FYS0NITG9iYjN3RVhIYl9lWUhDZDBHTk9CVUM0Wm1fek41YVJJUHBZMFJWTVdGUWN5V2s?oc=5","date":"2026-03-06","type":"pipeline","source":"Finviz","summary":"QURE Stock Crashes 32% in a Week: Here's What You Should Know - Finviz","headline":"QURE Stock Crashes 32% in a Week: Here's What You Should Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOOWNXVHBpUkxyUThqX1lJMy1RQjVlaHRBMldYZ0VTWUtlRy1xVkN5NDl5S2FRaXdjcVZ4ZzQ2eUprRXNwaG9PS0ZNUEdQNjFQRnFadmY2N0JxaC1XSnB5eER2aDBYaEVhYmVDcnV0a0Jxc0xmdWZnNEtDRHVMLVlmckVuNU9fb2VZUW9lNUZQQTRicFlJX3pmTlNLYWl6M0RDdVRUZ1Q3WHZJZm8?oc=5","date":"2026-03-03","type":"pipeline","source":"Seeking Alpha","summary":"uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade) (NASDAQ:QURE) - Seeking Alpha","headline":"uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade) (NASDAQ:QURE)","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPTlhoRFhkTHVRb2RjV3ZoQzVWYkNiVTFsZnU4bFhiQnJPZmd0LTQ3V1lxMFhUd3g5WFhsR09HY19PSWFSTXdpTlVfZ1pwUWtqZUt2UVpBazNsSVBVS3h4QnlZN3gwcFVZcnl0UkxoUWw4M2hkc1A3SFplWWhRa2E0eG1oaTZfQdIBjgFBVV95cUxNTkJ2Y25LN2NUUDN2NUZUX3k0NnRaVHRXVHk3dTRKWm5ENV9NeTREczNsLVRoa1lUdkdvZmdKUTI5VFFoQTk2enA1ZUJRc0YtNzg1QXdnS3Vsa3QxcVNkaXNmb1BQX3dTQnRVbEltLW1JcWcwU043alVqWjF2eFdQQW5yMW5GQkM0V1NTVlB3?oc=5","date":"2025-12-04","type":"pipeline","source":"Insider Monkey","summary":"uniQure N.V. (QURE): A Bear Case Theory - Insider Monkey","headline":"uniQure N.V. (QURE): A Bear Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQcm1BeWJaWlpad05Ea0l3TXdyTEZZZS1VVlFsMWRnU1hVZGFoT1RUTnVoRlFBY1RHX0w3WXlKZEJOMHdxQk1CRlFqNFJpRlhEeDlPcVlTWFJKNDlIQ2hHQjBGQTcwcUE5NVNMS0Rvenlyb3dWZGtaWi1BUE9GZ1VuZFBRZV9QS0ozZ0o4empKS29zQmU0aVlMNUVYSTFkQmpNQmlxMw?oc=5","date":"2025-11-04","type":"regulatory","source":"Seeking Alpha","summary":"UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE) - Seeking Alpha","headline":"UniQure: Controversy Abounds As Stock Price Halves On FDA News (NASDAQ:QURE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5xVWNOYllxNXpJSnFKcTdLWnJEREZuQm1DSTlrMnNMZm9UYWtfbHFrRjJmRXJxcXE0SmJHNDUxVFJOUUxjQVV3Wkhfbkg0YzVLS2w1aG9DQnZHQm9MeXlxNm9GcXNVaHFsYjNxSWVyYzVaYWhKNFpfN3FEWQ?oc=5","date":"2025-11-03","type":"regulatory","source":"Barron's","summary":"UniQure Stock (QURE) Plummets 67% on FDA News. Here’s Why. - Barron's","headline":"UniQure Stock (QURE) Plummets 67% on FDA News. Here’s Why. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQMHo2Z0J5d3E0N3luTGUxWldpSU5lc0JDN1Q3VzlHTW1iU2pheXl3X2VZSjlpS2RfMmZ6Tm1ITFZGX3hVSDFOcmtsdC1sLXpLRmJZSldnaDl0TV9XNWJfUGh6Y2tCVXpsNXJNVzY4OE1nR2VhT25EVWRjaXVsSGdtemV3dXRRWXF3QUpDX2E3WVFBdkppdVhmd0Qxb2d2cktKQmNxWW1nc2lUVFA4akhxWE1Lb0swSnh0X25nNVd3X1BsVU9EeDZBY0lQNTNuT0UySXdTWi1OLWJ2U2pS?oc=5","date":"2025-11-03","type":"regulatory","source":"Reuters","summary":"UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy - Reuters","headline":"UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE5JalhNZlgyaENlMWNtdThDbFB2TW53NkFKazFDWGYzdWFxRHU5RklCUk9YTXA3cG10MHB4RDJ3SFVhN3Z4VHZrRDRWRjBOZHlrVjRiZjVZaXZWd3ZRTlFfMFlTOHFjaTZsaV9UMkxUdS05UC1yM3c?oc=5","date":"2025-10-22","type":"pipeline","source":"Yahoo Finance","summary":"uniQure N.V. (QURE): A Bull Case Theory - Yahoo Finance","headline":"uniQure N.V. (QURE): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBmaVhhV0ttRjdzVVJGUDVJcWNFaUhHalZBLWFHWng1UXJlYlRmNktKVnpwRUZadU1ucDJoMzBBM2o2YmNrWllUOUxrY2dQUQ?oc=5","date":"2025-10-09","type":"pipeline","source":"StocksToTrade","summary":"uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade","headline":"uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNeGtTS0pkY0dzUDRQMEpRZm1xWmVBRDBoM3diejhwQ1NZWExzNjhRNlBlQ1J1TTlpUWRkUU5XekMwX3NIMGM0bThEZTF2RTNIZ3JPdDhyd01QVjd0SjcwLTRJbEY5MlBObTB5dV9KR1BzWUtqVWpZOUZqTVZwMFZxV2JIT1E2MkVuT2lGa2I2QlRTRjBnd2hQNFRyRmVaX1NiTkZzel9KQlRyNDFCM2U1S3lqdU9NS3RWSnZLYTZOeG41Zw?oc=5","date":"2025-09-25","type":"trial","source":"TradingView","summary":"QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - TradingView","headline":"QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPSWxPVGVCRUNkVTY2ZURvc2hNNWJPbU1VajVTcFFlUGhqY080U0Z2YmlhZHU4ZkR2WVZTUmpWUWNjVnlmQnZraWxFLWgzYlpiUDBocFp4aXRUOWwwUHdkVlVmQ1p0REViNGVEMEtHeGxrLVpueHl1bktnTm00alJnUlJpOWtKNHl2ZDFTZ09qZnBJbzBHbTdSc2w2dnc?oc=5","date":"2025-09-24","type":"pipeline","source":"TechStock²","summary":"uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook - TechStock²","headline":"uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook - TechStock²","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-01","type":"pipeline","source":"simplywall.st","summary":"Institutional investors are uniQure N.V.'s (NASDAQ:QURE) biggest bettors and were rewarded after last week's US$53m market cap gain - simplywall.st","headline":"Institutional investors are uniQure N.V.'s (NASDAQ:QURE) biggest bettors and were rewarded after last week's US$53m mark","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Spark Therapeutics, Inc.","Sangamo Therapeutics, Inc."],"therapeuticFocus":["Hemophilia","Huntington's Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":13107000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":13107000,"period":"2017-12-31"},{"value":25098000,"period":"2016-12-31"},{"value":10578000,"period":"2015-12-31"},{"value":6141000,"period":"2014-12-31"}],"grossProfit":14412000,"grossProfitHistory":[{"period":"2025-12-31","value":14412000},{"period":"2024-12-31","value":8792000},{"period":"2023-12-31","value":2215000},{"period":"2022-12-31","value":103140000}],"rdSpend":140673000,"rdSpendHistory":[{"period":"2025-12-31","value":140673000},{"period":"2024-12-31","value":143782000},{"period":"2023-12-31","value":214864000},{"period":"2022-12-31","value":197591000}],"sgaSpend":65337000,"operatingIncome":-187827000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-187827000},{"period":"2024-12-31","value":-182180000},{"period":"2023-12-31","value":-282486000},{"period":"2022-12-31","value":-144246000}],"netIncome":-198971000,"netIncomeHistory":[{"period":"2025-12-31","value":-198971000},{"period":"2024-12-31","value":-239556000},{"period":"2023-12-31","value":-308478000},{"period":"2022-12-31","value":-126789000}],"eps":-3.46,"epsHistory":[{"period":"2025-12-31","value":-3.46},{"period":"2024-12-31","value":-4.92},{"period":"2023-12-31","value":-6.47},{"period":"2022-12-31","value":-2.71}],"cash":80240000,"cashHistory":[{"period":"2025-12-31","value":80240000},{"period":"2024-12-31","value":158930000},{"period":"2023-12-31","value":241360000},{"period":"2022-12-31","value":228012000}],"totalAssets":824908000,"totalLiabilities":626007000,"totalDebt":63393000,"equity":198901000,"operatingCashflow":-177963000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-177963000},{"period":"2024-12-31","value":-182728000},{"period":"2023-12-31","value":-145929000},{"period":"2022-12-31","value":-145060000}],"capex":-439000,"capexHistory":[{"period":"2025-12-31","value":-439000},{"period":"2024-12-31","value":-11689000},{"period":"2023-12-31","value":-7154000},{"period":"2022-12-31","value":-17688000}],"freeCashflow":-178402000,"dividendsPaid":null,"buybacks":null,"employees":221,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":20068000,"ebit":-39016000,"ebitda":-36060000,"period":"2026-03-31","revenue":3562000,"epsBasic":-0.85,"netIncome":-53535000,"rdExpense":29176000,"epsDiluted":-0.85,"grossProfit":3343000,"operatingIncome":-44269000},{"sga":21491000,"ebit":-26429000,"ebitda":-23459000,"period":"2025-12-31","revenue":5568000,"epsBasic":null,"netIncome":-37086000,"rdExpense":34784000,"epsDiluted":null,"grossProfit":5133000,"operatingIncome":-51494000},{"sga":19438000,"ebit":-55182000,"ebitda":-51550000,"period":"2025-09-30","revenue":3701000,"epsBasic":-1.38,"netIncome":-80529000,"rdExpense":34366000,"epsDiluted":-1.38,"grossProfit":3303000,"operatingIncome":-49489000},{"sga":13500000,"ebit":-21703000,"ebitda":-18073000,"period":"2025-06-30","revenue":5262000,"epsBasic":-0.69,"netIncome":-37719000,"rdExpense":35383000,"epsDiluted":-0.69,"grossProfit":4606000,"operatingIncome":-42885000},{"sga":10908000,"ebit":-28032000,"ebitda":-23505000,"period":"2025-03-31","revenue":1567000,"epsBasic":-0.82,"netIncome":-43637000,"rdExpense":36140000,"epsDiluted":-0.82,"grossProfit":1370000,"operatingIncome":-37372000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.91,"netIncome":null,"rdExpense":null,"epsDiluted":-0.91,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":27.07,"previousClose":29.17,"fiftyTwoWeekHigh":71.5,"fiftyTwoWeekLow":8.73,"fiftyTwoWeekRange":"8.73 - 71.5","fiftyDayAverage":17.85,"twoHundredDayAverage":25.87,"beta":0.87,"enterpriseValue":1798784512,"forwardPE":-9.5,"priceToBook":8.48,"priceToSales":94.36,"enterpriseToRevenue":99.42,"enterpriseToEbitda":-10.29,"pegRatio":0,"ebitda":-174856992,"ebitdaMargin":0,"freeCashflow":-103697624,"operatingCashflow":-172106000,"totalDebt":545656000,"debtToEquity":365.4,"currentRatio":10.4,"returnOnAssets":-17,"returnOnEquity":-228.2,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":11,"targetMeanPrice":39.33,"targetHighPrice":94.82,"targetLowPrice":13.97,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.5,"institutionHeldPercent":101.9,"sharesOutstanding":63067485,"floatShares":49889534,"sharesShort":10784518,"shortRatio":7.03,"shortPercentOfFloat":17.1,"epsTrailing":-3.49,"epsForward":-2.86,"revenuePerShare":0.3,"bookValue":3.19,"officers":[{"age":53,"name":"Mr. Matthew Craig Kapusta CPA","title":"CEO & Executive Director"},{"age":52,"name":"Mr. Christian  Klemt","title":"CFO, Principal Financial Officer & GM of Amsterdam Site"},{"age":63,"name":"Dr. Jeannette  Potts J.D., Ph.D.","title":"Chief Legal & Compliance Officer and Corporate Secretary"},{"age":60,"name":"Dr. Walid  Abi-Saab M.D.","title":"Chief Medical Officer"},{"age":null,"name":"Prof. Hugo  Katus","title":"Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany"},{"age":null,"name":"Dr. Amin  Abujoub Ph.D.","title":"Chief Technical Operations Officer"},{"age":57,"name":"Mr. Richard  Porter Ph.D.","title":"Chief Business & Scientific Officer"},{"age":null,"name":"Ms. Chiara Elizabeth Russo","title":"Senior Director of Investor Relations"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.uniqure.com","phone":"31 20 240 6000"}}